|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 24, No 6 (February 20), 2006: pp. 884-890 © 2006 American Society of Clinical Oncology. DOI: 10.1200/JCO.2005.02.4505 White Matter Anisotropy in Post-Treatment Childhood Cancer Survivors: Preliminary Evidence of Association With Neurocognitive FunctionFrom the Departments of Diagnostic Radiology, Clinical Oncology, Clinical Psychology, Nursing Studies, Psychiatry, Paediatric and Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong; GE Medical Systems Asia, Hong Kong, China Address reprint requests to Pek-Lan Khong, Department of Diagnostic Radiology, Blk K, Rm 406, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Rd, Hong Kong; e-mail: plkhong{at}hkucc.hku.hk
PURPOSE: We aim to determine if the loss of white matter fractional anisotropy (FA), measured by diffusion tensor magnetic resonance imaging (DTI), in post-treatment childhood medulloblastoma (MED) and acute lymphoblastic leukemia (ALL) survivors correlate with intelligence quotient (IQ) scores.
MATERIALS AND METHODS: MED and ALL survivors (n = 30; 20 male, 10 female; age range, 6.0 to 22.1 years; mean, 13.1 years) were recruited for DTI and IQ tests. In this cross-sectional study, age-matched normal control (n = 55; 32 male, 23 female; age range, 6.0 to 23 years; mean, 12.1 years) DTI was obtained to compute percentage difference in white matter FA (
RESULTS: CONCLUSION: Our preliminary findings suggest that white matter FA may be a clinically useful biomarker for the assessment of treatment-related neurotoxicity in post-treatment childhood cancer survivors.
Treatment-induced neurotoxicity is a major cause of neurobehavioral morbidity in childhood cancer survivors affecting diverse aspects of cognitive function, especially attention, memory, and processing speed, which, in turn, affect intelligence quotient (IQ) and academic achievement.1-7 With therapeutic advancements and improving long-term survivals, there is a greater and more urgent need for attention to neurocognitive outcomes, an important domain contributing to the quality of life of these children. The assessment of treatment-induced neurotoxicity using conventional magnetic resonance neuroimaging techniques have been limited, with most studies reporting a lack of correlation between the presence of leukoencephalopathy on conventional magnetic resonance imaging (MRI) and clinical symptoms or neurocognitive tests.8-11 Advanced MRI techniques have shown more promising results. Volumetric measurements of normal appearing white matter in medulloblastoma (MED) survivors have been found to be reduced compared with normal controls,12 and the severity of volume loss correlates with young age at cranial irradiation,12 cranial irradiation dose, and IQ scores.5,6,12 This supports the fact that cerebral white matter is the neuroanatomic substrate for treatment-induced neurotoxicity. Also, magnetic resonance spectroscopy studies have generally shown a reduction in N-acetyl aspartate ratios in the white matter of childhood acute lymphoblastic leukemia (ALL) children, although no correlation has been found with neurocognitive scores.13,14 We have used a new sequence in MRI, diffusion tensor MRI (DTI), to measure the loss of fractional anisotropy (FA) in the white matter of childhood cancer survivors.15,16 DTI is a technique that is able to quantitate the diffusion of water molecules in the brain. In white matter, the diffusion process is highly directional because of axonal fibers running in parallel, making this technique advantageous for the assessment of white matter.17 This property, termed diffusion anisotropy, can be quantified by the index FA. When white matter microstructure is disrupted because of pathology, the abnormality can be detected and quantified by the loss of FA. Compared with volumetric measurements, this method potentially has the advantage of more sensitive detection of subtle and early changes that occur in the microstructure and organization of white matter fiber tracts. We have shown that white matter FA (WMFA) is less in childhood MED survivors compared with normal control patients,15,16 and that the difference correlates with known risk factors of neurotoxicity,18 suggesting that FA may be used as a biomarker of treatment-induced white matter damage reflecting the status of tissue microstructure and architecture. In a cross-sectional study of childhood MED and ALL survivors, we aim to determine if FA measurement correlates with neurocognitive function, by the assessment of IQ scores.
Patient Demographics Consecutive MED and ALL survivors who were free of the primary disease, completed treatment at least 1 year ago, and were at least 6 years of age were recruited from the Pediatric Oncology Unit of our hospital for DTI and IQ tests. Informed consent was obtained from the patient or parent and the study was approved by the hospital institutional review board. A total of 30 patients (20 male, 10 female; age range, 6.0 to 22.1 years; mean age, 13.1 years) were recruited, of which 12 were MED survivors and 18 were ALL survivors. All the MED survivors belonged to our previous cohort studied for the association of FA with risk factors of neurotoxicity.18 IQ scores were not analyzed then. All MED survivors (9 male, 3 female; age range, 6 to 20.6 years; mean, 11.8 years) underwent tumor resection, craniospinal irradiation, and chemotherapy. The whole brain was irradiated with lateral opposing fields 23.4 to 40 Gy in 1.8 to 2 Gy daily fractions. Afterward, additional boost was given to the posterior cranial fossa with reduced lateral opposing fields or with three-dimensional conformal radiotherapy. Three patients had posterior cranial fossa boost with three-dimensional conformal radiotherapy. Total dose to the posterior cranial fossa ranged from 50 to 55.8 Gy. Total craniospinal irradiation dose was 23.4 Gy (n = 3), 30.6 Gy (n = 3), 36 Gy (n = 5), and 40 Gy (n = 1). The variation in dosage is, in part, because of the change of the protocol in recent years and also, in part, because of the differences in their disease status. Chemotherapy regime was vincristine, cyclophosphamide, cisplatin and VP16 (baby Pediatric Oncology Group protocol) for children diagnosed before 2000 or CCNU (lomustine), cisplatin, and vincristine (CCV protocol) for children diagnosed after 2000. All ALL survivors (11 male, 7 female; age range, 6.8 to 22 years; mean, 13.9 years) were treated with standardized intrathecal and systemic chemotherapy regimes. Patients received intrathecal methotrexate and high-dose methotrexate in doses varying from 2 to 5 g/m2 for three to four doses. Before October 1997, chemotherapy was according to the HKALL93 protocol (based on the United Kingdom Medical Research Council protocols for childhood ALL, UKALLX1). From October 1997, the chemotherapy regime was altered to the HKALL97 protocol (based on the Berlin-Frankfurt-Munster study group protocol, ALL-BFM 95). The cranial irradiation dose for high-risk patients was 18 Gy in the HKALL93 protocol and 12 Gy in the HKALL97 protocol. Nine ALL survivors underwent irradiation for CNS prophylaxis and/or CNS disease (6 males, 3 females; age range, 7.4 to 22 years; mean, 14.8 years) and nine did not (5 males, 4 females; age range, 6.8 to 17.7 years; mean, 13.1 years). Cranial irradiation dose was 12 Gy (n = 2), 18 Gy (n = 5), and 24 Gy (n = 2, for CNS involvement).
Patient demographic data is summarized in Table 1. Fifty-five healthy age-matched children (32 male, 23 female; age range, 6.0 to 23 years; mean, 12.1 years) were selected as controls for DTI scans after institutional review board approval and informed consent was obtained from the subjects, patients, or parents. These subjects were volunteer healthy control subjects or patients who underwent MRI of the brain for clinical indications such as headache or congenital sensorineural hearing loss and were subsequently confirmed to have no neurologic deficit by clinical examination and normal MRI scans. The control subjects were imaged with the same DTI protocol as the patients and were divided into four groups by age: Group A (n = 13; age range, 6.0 to 8.9 years; mean, 7.7 years), Group B (n = 18; age range, 9.0 to 11.9 years; mean, 10.2 years), Group C (n = 11; age range, 12.0 to 14.9 years; mean, 13.6 years), and Group D (n = 13; age range, 15.0 to 23.0 years; mean, 17.9 years) for analysis (see below for
Data Acquisition MRI was performed using a Signa 1.5 Tesla imager (General Electric Medical Systems, Milwaukee, WI) with a standard head coil. DTI data was acquired using single-shot spin-echo echo-planar imaging with TR = 10,000 ms, TE = 100 ms, acquisition matrix = 128 x 128 and field of view = 28 cm. Using a slice thickness of 5 mm with 1.5 mm gap, images were acquired through the entire brain (18 or 19 images). Diffusion-sensitizing gradient encoding was applied in 25 directions by using a diffusion-weighted factor b = 1,200 s/mm2, and one image was acquired without use of a diffusion gradient, ie, b = 0 s/mm2. The DTI imaging time was approximately 5 minutes.
Image Processing
Neuropsychologic Tests
Statistical Analysis
We also tested the unadjusted effects of All statistical analyses were performed using the statistical package SPSS for Windows (Version 11.0, SPSS, Chicago, IL). A P value of less than .05 was considered to indicate statistical significance.
Control and Patient Group Demographics There were no significant differences found between age (Mann-Whitney U test, P = .316), sex (Fisher's exact test, P = .492), educational levels (Mann-Whitney U test, P = .899), and socioeconomic status (Mann-Whitney U test, P = .306) between the control and patient groups.
Mean WMFA and
IQ Scores
Statistical Analysis for FA% Versus IQ ScoresMultivariate regression analysis with FA% as the only independent variable found significant correlations with FSIQ (Fig 1; adjusted r2 = 0.434; P < .001), VIQ (Fig 2; adjusted r2 = 0.234; P = .004), and PIQ (Fig 3; adjusted r2 = 0.515; P < .001). Note that the overall significance of FA% with the three IQ scores was significant (Wilk's Lambda test, P < .001). In stage 1 of multivariate regression analysis using sex, educational level, and socioeconomic status as independent variables, we found that these variables were all not significant factors affecting IQ scores (Wilk's lambda test, P = .686, P = .490, and P = .232, respectively). Therefore, these variables were excluded from further multivariate analysis. In stage 2, after adjusting for the effects of age at treatment, irradiation dose and time interval from treatment, FA% remained as a significant factor of FSIQ (adjusted r2 = 0.439; P < .001), VIQ (adjusted r2 = 0.237; P = .028), and PIQ (adjusted r2 = 0.491; P < .001; Table 3).
Using 85 as a cutoff for below average IQ score, receiver operating characteristic curve analysis showed that the best FA% value to predict less than 85 scores in FSIQ, VIQ, and PIQ was 3.3%. The sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio for predicting FSIQ less than 85, VIQ less than 85, and PIQ less than 85 using FA % = 3.3% are presented in Table 4.
In a cohort of childhood post-treatment MED and ALL survivors, we found that FA% (difference between patient FA and age-matched healthy control group FA normalized to the control group FA) of the white matter is significantly correlated with FSIQ, VIQ, and PIQ before and after adjusting for age at treatment, irradiation dose, and time interval since treatment. In addition, a FA% cutoff of 3.3% provided a high specificity (100%), high negative predictive value (100%), and low negative likelihood ratio (0) for FSIQ and PIQ of less than 85. Together with high positive likelihood ratios, our results suggest that FA is a clinically useful indicator of cognitive outcome in this cohort of childhood cancer survivors. Positive predictive values were found to be moderate and this can, in part, be explained by the low prevalence of IQ scores less than 85 in our cohort.
It has been shown that white matter FA increases nonlinearly with age with the steepest increase occurring in the first few years of life, reaching asymptote at about 6 years in the internal capsule and corpus callosum and at about 8 years in the peripheral white matter of the centrum semiovale.19-22 This is attributed to several factors, including myelination, and increases in the number of axons, axonal diameter, and fiber coherence. Hence, we have used age-matched patient controls to derive the The association of DTI indices with cognitive function has been shown in both normal and diseased populations. Nagy et al23 found that the development of cognitive abilities in childhood is correlated with maturation of white matter; specifically, working memory and reading abilities were found to correlate with increased FA in the superior and inferior left frontal lobe and the left temporal lobe, respectively. Peng et al24 studied children with early chronic malignant phenylketonuria and found that VIQ, PIQ, and FSIQ were related to alteration of diffusion indices in the parieto-occipital white matter. Similar correlations have been found in minimal cognitive impairment and Alzheimer's disease,25 ischemic leukoaraiosis,26 and relapsing-remitting multiple sclerosis.27 In our cohort of childhood cancer survivors, apart from white matter damage from cranial irradiation and chemotherapy, contributory causes of cognitive decline in MED survivors include the primary effects of the tumor in the cerebellum, cerebellar resection,28,29 and its complications such as posterior fossa syndrome and hydrocephalus;30 and in ALL survivors, cortical atrophy and mineralizing microangiopathy are known sequelae of intrathecal methotrexate chemotherapy, which affect cognition.31 Therefore, white matter FA, which could be an indicator of myelin and/or axonal integrity, only partially accounts for cognitive function in our cohort. We note that the IQ scores of our cohort are relatively high compared with other studies, especially the MED survivors. Mulhern et al12 and Palmar et al34 found the IQ scores in MED survivors to be between 80 and 85. The IQ scores of ALL survivors have been found to be generally higher and often within the normal range.31 This is presumably partly because of the lower cranial irradiation dose in these patients. However, most studies have found some decline in one or more aspects of cognitive function when individual subsets scores are assessed.31 Since the cognitive impairment in ALL survivors is relatively mild and difficult to detect, this may be evident only when a matching control group IQ is used for comparison.32,33 High IQ scores in our cohort may reflect selection bias, a relatively high age at diagnosis and treatment of our MED group (mean age at diagnosis, 8.5 years, which is older than in most studies), and conservative irradiation doses. In our cohort, the lack of a significant difference in the IQ scores between MED survivors and ALL survivors may be because IQ tests were performed at a shorter interval since treatment in the former group, as it has been shown that IQ scores progressively decline with interval since treatment.4,34,35 The subtest with most frequent below average score in our cohort was digit symbol/coding (34.5%). This subtest is a test of psychomotor performance and involves motor persistence, sustained attention, response speed, and visuomotor coordination. It is considered a sensitive test of brain damage and tends to be affected regardless of the locus of the lesion and is in keeping with the diffuse white matter damage found after whole brain irradiation.
Our study is limited by a relatively small, heterogeneous cohort with varied treatment protocols and disease processes. Our findings may, therefore, only be specific to this cohort of patients and should not be generalized to other types of cohorts. In addition, the small subject numbers may result in the lack of power for determination of the effect of some factors in the multivariate regression analysis. The age ranges applied to the control subjects in this study are arbitrary and were selected such that they were reasonably small. The use of mean FA reference values of an age-range, albeit small, instead of exact age-match is another limitation that has been discussed in our previous publication.18 The cross-sectional nature of the study does not allow the assessment of developmental trends in IQ and FA. In a prospective study, if FA decline is found to herald IQ deterioration and is able to indicate damage before the completion of treatment, it may be used as a parameter to effect change in treatment strategy. Also, two patients had a prolonged time lag of more than 1 year between IQ test and DTI, which may have affected the accuracy of our results. Finally, in the assessment of cognitive function, we did not evaluate more specific tests to tap specific cognitive abilities, which have been reported to decline after cranial irradiation, for example, memory and learning, attention and information processing speed. These tests may be more sensitive to the detection of cognitive decline and it may be possible that some of these tests have a stronger correlation with In conclusion, our findings suggest that DTI, using FA as a biomarker, may be a clinically useful tool for the assessment of treatment-related neurotoxicity and can be used as an adjunct to IQ scores. Longitudinal studies should be performed with close time points after treatment to determine the patterns of FA change and if loss of FA can be used to predict subsequent IQ decline. Apart from the assessment of neurotoxicity, this biomarker may potentially be useful in the assessment of timing and application of neurotoxic treatments and to test the effectiveness of neuroprotective drugs.
The authors indicated no potential conflicts of interest.
Supported by Hong Kong RGC CERG Grant Ref: HKU 7416/03M. Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
1. Packer RJ, Sposto R, Atkins TE, et al: Quality of life in children with primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Pediatr Neurosci 13:169-175, 1987[Medline] 2. Johnson DL, McCabe MA, Nicholson HS, et al: Quality of long-term survival in young children with medulloblastoma. J Neurosurg 80:1004-1010, 1994[Medline] 3. Walter AW, Mulhern RK, Gaijar A, et al: Survival and neurodevelopmental outcome of young children with medulloblastoma at St. Jude Children's Research Hospital. J Clin Oncol 17:3720-3728, 1999 4. Spiegler BJ, Bouffet E, Greenberg ML, et al: Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol 22:706-713, 2004 5. Mulhern RK, White HA, Glass JO, et al: Attentional functioning and white matter integrity among survivors of malignant brain tumors of childhood. J Int Neuropsychol Soc 10:180-189, 2004[CrossRef][Medline] 6. Reddick WE, White HA, Glass JO, et al: Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors. Cancer 97:2512-2519, 2003[CrossRef][Medline] 7. Mulhern RK, Reddick WE, Palmer SL, et al: Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann Neurol 46:834-841, 1999[CrossRef][Medline] 8. Ball WS, Prenger EC, Ballard ET: Neurotoxicity of radio/chemotherapy in children: Pathologic and MR correlation. AJNR Am J Neuroradiol 13:761-776, 1992[Medline] 9. Curran WJ, Hecht-Leavitt C, Schut L, et al: Magnetic resonance imaging of cranial radiation lesions. Int J Radiat Oncol Biol Phys 13:1093-1098, 1987[Medline] 10. Constine LS, Konski A, Ekholm S, et al: Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phys 15:319-330, 1988[CrossRef][Medline] 11. Tsuruda JS, Kortman KE, Bradley WG, et al: Radiation effects on cerebral white matter: MR evaluation. AJR Am J Roentgenol 149:165-171, 1987 12. Mulhern RK, Palmer SL, Reddick WE, et al: Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 19:472-479, 2001 13. Chu WCW, Chik KW, Chan YL, et al: White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: Longitudinal study with MR imaging and H MR spectroscopy. Radiology 229:659-669, 2003 14. Chan YL, Roebuck DJ, Yuen MP, et al: Long-term cerebral metabolite changes on proton magnetic resonance spectroscopy in patients cured of acute lymphoblastic leukemia with previous intrathecal methotrexate and cranial irradiation prophylaxis. Int J Radiat Oncol Biol Phys 50:759-763, 2001[CrossRef][Medline] 15. Khong PL, Kwong DLW, Chan GCF, et al: Diffusion-tensor imaging (DTI) for the detection and quantification of treatment-induced white matter injury in children with medulloblastoma: A pilot study. AJNR Am J Neuroradiol 24:734-740, 2003 16. Leung LHT, Ooi GC, Kwong DL, et al: White-matter diffusion anisotropy after chemo-irradiation: A statistical parametric mapping study and histogram analysis. Neuroimage 21:261-268, 2004[CrossRef][Medline] 17. LeBihan D, Mangin JF, Poupon C, et al: Diffusion tensor imaging: Concepts and applications. J Magn Reson Imag 13:534-546, 2001[CrossRef][Medline] 18. Khong PL, Leung LH, Chan GCF, et al: White matter anisotropy in childhood medulloblastoma survivors: Association with neurotoxicity risk factors. Radiology 236:647-652 19. Nomura Y, Sakuma H, Tagami T, et al: Diffusional anisotropy of the human bran assessed with diffusion-weighted MR: Relation with normal brain development and aging. AJNR Am J Neuroradiol 15:231-238, 1994[Abstract] 20. Morriss MC, Zimmerman RA, Bilaniuk LT, et al: Changes in brain water diffusion during childhood. Neuroradiology 41:929-934, 1999[CrossRef][Medline] 21. Mukherjee P, Miller JH, Shimony JS, et al: Normal brain maturation during childhood: Developmental trends characterized with diffusion-tensor MR imaging. Radiology 221:349-358, 2001 22. Philip JV, Mukherjee P, Neil JJ, et al: White matter maturation in older children demonstrated with diffusion tensor MRI. Proc Intl Soc Mag Reson Med 9:409, 2001 23. Nagy Z, Westerberg H, Klingberg T, et al: Maturation of white matter is associated with the development of cognitive functions during childhood. J Cogn Neurosci 16:1227-1233, 2004[CrossRef][Medline] 24. Peng SSF, Tseng WYI, Chien YH, et al: Diffusion tensor images in children with early-treated, chronic, malignant phenylketonuric: Correlation with intelligence assessment. AJNR Am J Neuroradiol 25:1569-1574, 2004 25. Kantarci K, Jack CR, Xu YC, et al: Mild cognitive impairment and Alzheimer disease: Regional diffusivity of water. Radiology 219:101-107, 2001 26. O'Sullivan M, Morris RG, Huckstep B, et al: Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. J Neurol Neurosurg Psychiatry 75:441-447, 2004 27. Rovaris M, Iannucci G, Falautano M, et al: Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: An exploratory study with diffusion tensor MR imaging. J Neurol Sci 195:103-109, 2002[CrossRef][Medline] 28. Steinlin M, Imfeld S, Zulauf P, et al: Neuropsychological long-term sequelae after posterior fossa tumour resection during childhood. Brain 126:1998-2008, 2003 29. Riva D, Giorgi C: The cerebellum contributes to higher functions during development: Evidence from a series of children surgically treated for posterior fossa tumours. Brain 123:1051-1061, 2000 30. Mabbott DJ, Spiegler BJ, Greenberg ML, et al: Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J Clin Oncol 23:2256-2263, 2005 31. Moleski M: Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol 15:603-630, 2000[CrossRef][Medline] 32. Ochs J, Mulhern R, Fairclough D, et al: Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: A prospective study. J Clin Oncol 9:145-151, 1991 33. Giralt J, Ortega JJ, Olive T, et al: Long-term neuropsychologic sequelae of childhood leukemia: Comparison of two CNS prophylactic regimens. Int J Radiat Oncol Biol Phys 24:49-53, 1992[Medline] 34. Palmer SL, Goloubeva O, Reddick WE, et al: Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis. J Clin Oncol 19:2302-2308, 2001 35. Palmer SL, Gaijar A, Reddick WE, et al: Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology 17:548-555, 2003[CrossRef][Medline] Submitted April 20, 2005; accepted December 5, 2005.
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|